PCP
KYMR icon

Perbak Capital Partners’s Kymera Therapeutics KYMR Stock Holding History

Perbak Capital Partners’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$537K Buy
6,443
+3,805
+144% +$301K 0.13% 179
2025
Q4 		$205K Sell
2,638
-4,866
-65% -$329K 0.06% 217
2025
Q3 		$425K Buy
+7,504
New +$338K 0.07% 243

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Perbak Capital Partners's KYMR Position: Q1 2026 in Review

Perbak Capital Partners increased its Kymera Therapeutics (KYMR) stake by 144% in Q1 2026, buying an estimated $301K and bringing the position to 6,443 shares worth $537K. The position accounts for 0.13% of the portfolio, ranked #179.

Perbak Capital Partners first reported a position in KYMR in Q3 2025 and has held it in 3 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Perbak Capital Partners held 6,443 shares of Kymera Therapeutics worth $537K as of Q1 2026.
  • Perbak Capital Partners bought 3,805 Kymera Therapeutics shares in Q1 2026, an estimated $301K.
  • Kymera Therapeutics made up 0.13% of Perbak Capital Partners's portfolio in Q1 2026, its #179 holding.
  • Perbak Capital Partners first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.